Medicaments: containing antibiotics other than penicillins, streptomycins and their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale)

In 2024, medicaments: containing antibiotics other than penicillins, streptomycins and their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) trade exhibited significant decline, with global flows reaching $1,072,068,539 and a three-year compound annual growth rate of +2.7% (five-year: +2.6%). The all-time peak of $1,897,118,029 was recorded in 2009; the current level is 43% below that high-water mark.

Over the 30-year observation window (1995–2024), 52% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is steady (+0.8% acceleration).

The World Trade Flows Characterization classifies medicaments: containing antibiotics other than penicillins, streptomycins and their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) as "One-way trade" in the high price range price segment, providing additional context for market positioning and competitive dynamics.

The supply side is concentrated (Herfindahl-Hirschman Index 0.262). The three largest exporters — Italy ($439.8M), China ($395.4M), and Netherlands ($40.4M) — collectively dominate supply flows. The leading exporter has grown at +23.3% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.088). The three largest import markets are United States ($272.9M), Switzerland ($119.4M), and Germany ($41.0M). The largest importing market sources from 21 different supplying countries.

Estimated substitution elasticity: -22.15. Buyers are highly price-sensitive and can switch between suppliers relatively easily.

The dominant trade corridor is Italy → United States at $241.6M, representing 88.5% of the importer's total demand.

The volatility score for medicaments: containing antibiotics other than penicillins, streptomycins and their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) is 11 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, contracting demand signals caution before committing resources. The concentrated supply structure suggests high barriers but also potential opportunity if dominant suppliers face disruption or capacity constraints.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.